NovaBridge Biosciences (NBP) Total Liabilities (2018 - 2022)
NovaBridge Biosciences (NBP) has disclosed Total Liabilities for 5 consecutive years, with $163.6 million as the latest value for Q4 2022.
- Quarterly Total Liabilities changed 0.43% to $163.6 million in Q4 2022 from the year-ago period, while the trailing twelve-month figure was $163.6 million through Dec 2022, changed 0.43% year-over-year, with the annual reading at $168.7 million for FY2022, 3.23% up from the prior year.
- Total Liabilities for Q4 2022 was $163.6 million at NovaBridge Biosciences, roughly flat from $162.9 million in the prior quarter.
- The five-year high for Total Liabilities was $163.6 million in Q4 2022, with the low at $60.1 million in Q4 2018.
- Average Total Liabilities over 5 years is $117.6 million, with a median of $106.6 million recorded in 2020.
- The sharpest move saw Total Liabilities soared 57.67% in 2019, then increased 0.43% in 2022.
- Over 5 years, Total Liabilities stood at $60.1 million in 2018, then skyrocketed by 57.67% to $94.8 million in 2019, then grew by 12.49% to $106.6 million in 2020, then skyrocketed by 52.79% to $162.9 million in 2021, then increased by 0.43% to $163.6 million in 2022.
- According to Business Quant data, Total Liabilities over the past three periods came in at $163.6 million, $162.9 million, and $106.6 million for Q4 2022, Q4 2021, and Q4 2020 respectively.